






































Constipation Predominant Irritable Bowel Syndrome
and Functional Constipation Are Not Discrete Disorders:
A Machine Learning Approach
James K. Ruffle, MBBS, BSc1,2,3, Linda Tinkler, MSc4, Christopher Emmett, MD, FRCS4, Alexander C. Ford, MBChB, FRCP5,
Parashkev Nachev, FRCP, PhD3, Qasim Aziz, FRCP, PhD1, Adam D. Farmer, FRCP, PhD1,6 and Yan Yiannakou, MBChB, MRCP, MD4
INTRODUCTION: Chronicconstipation isclassified into2mainsyndromes, irritablebowel syndromewithconstipation (IBS-C)
and functional constipation (FC), on the assumption that they differ along multiple clinical characteristics
and are plausibly of distinct pathophysiology. Our aim was to test this assumption by applying machine
learning to a large prospective cohort of comprehensively phenotyped patients with constipation.
METHODS: Demographics, validated symptom and quality of life questionnaires, clinical examination findings, stool
transit, and diagnosis were collected in 768 patients with chronic constipation from a tertiary center. We
used machine learning to compare the accuracy of diagnostic models for IBS-C and FC based on single
differentiating features such as abdominal pain (a “unisymptomatic”model) vs multiple features
encompassing a range of symptoms, examination findings and investigations (a “syndromic”model) to
assess the grounds for the syndromic segregation of IBS-C and FC in a statistically formalized way.
RESULTS: Unisymptomatic models of abdominal pain distinguished between IBS-C and FC cohorts near perfectly
(area under the curve 0.97). Syndromic models did not significantly increase diagnostic accuracy (P >
0.15). Furthermore, syndromic models from which abdominal pain was omitted performed at chance-
level (area under the curve 0.56). Statistical clustering of clinical characteristics showed no structure
relatable to diagnosis, but a syndromic segregation of 18 features differentiating patients by impact of
constipation on daily life.
DISCUSSION: IBS-C and FC differ only about the presence of abdominal pain, arguably a self-fulfilling difference given
that abdominal pain inherently distinguishes the 2 in current diagnostic criteria. This suggests that they
are not distinct syndromes but a single syndrome varying along one clinical dimension. An alternative
syndromic segregation is identified, which needs evaluation in community-based cohorts. These results
have implications for patient recruitment into clinical trials, future disease classifications, and
management guidelines.
SUPPLEMENTARYMATERIAL accompanies this paper at http://links.lww.com/AJG/B619, http://links.lww.com/AJG/B620, http://links.lww.com/AJG/B621, http://links.
lww.com/AJG/B622, http://links.lww.com/AJG/B623, http://links.lww.com/AJG/B624, http://links.lww.com/AJG/B632
Am J Gastroenterol 2021;116:140–149. https://doi.org/10.14309/ajg.0000000000000816
INTRODUCTION
Chronic constipation is a common symptom, with a pooled prev-
alence of 14% (1). Although there are multiple causes of chronic
constipation, among the most prevalent are irritable bowel syn-
drome with constipation (IBS-C) and functional constipation (FC).
These functional bowel disorders are delineated by the Rome
classification, now in its fourth iteration (2–5), based on the presence
or absenceof recurrent abdominal pain and its relation todefecation,
stool frequency, or appearance (Table 1 and Table 2) (2,3).
A syndrome, bydefinition, is “agroupof signs and symptoms that
occur together and characterize a particular abnormality or condi-
tion” (6). Segregating syndromes with very similar symptom profiles
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into single entities implies the presence of a number of differences,
plausibly these would include differences in causal mechanisms and
therefore would be worth preserving. If 2 disorders differ only by a
single feature, varying “unisymptomatically,” the basis for expecting
dissimilarityof causalmechanisms ismuchweaker.Moreover, if such
segregation is predetermined by diagnostic criteria only, as opposed
to pathophysiological or treatment response differences, then its
value is uncertain. Previous studies, including those from primary
care, epidemiological and smaller-scale investigatory studies, have
questioned themutual exclusivity of IBS-C andFCas disease entities,
suggesting instead that the 2 lie on a single spectrum (7–12). Should
this be the case, the differentiation of the 2 disorders as discrete is
arguably confusing for both the patient and healthcare provider. An
example of this would be a previous study illustrating that patients
with FC and IBS-C will frequently switch diagnostic label over time,
from IBS-C to FC, and vice versa (8). Management algorithms and
treatment trials are often constrained by these categories, being
limited to either IBS-C or FC, so establishing the validity of this
differentiation is crucial to clinical practice.
Previous studies, although informative in this regard, have
generally focusedonone specific aspect of clinical data only, suchas
reporting demographic differences between IBS-C and FC. The
advent of data science and machine learning represents an op-
portunity to model the interpretation of complex, multidimen-
sional data, such as the clinical history, patient-reported outcome
measures, examination, and investigation findings (13–17). In
addition, machine learning or graph-based network analyses pro-
vide an innovative ability for models to learn complex interaction
between large numbers of patient factors, for instance, how a given
patient’s demographic, clinical history, psychophysiology, exami-
nation findings, and investigations all interact to provide an overall
disease phenotype (13). Given these disorders are inherently
complex, involving multiple disease facets, it is argued the use of
such an approach is wise.
Therefore, theprimary aimof this studywas to assess the valueof
Rome criteria-delineated diagnostic classification labels in patients
with symptoms of chronic constipation using a machine learning
approach. Our hypothesis was that the diagnostic groups would
differ along viscerosensory measures, especially pain, but otherwise
would be equivalent, therefore evidencing that IBS-C and FC are
together a single syndrome varying along one dimension, as op-
posed to 2 distinct syndromes. We tested this hypothesis by com-
paring thediagnostic accuracy of “unisymptomatic” vs “syndromic”
statistical models, relying on machine learning to make compari-
sons between complex patterns of clinical features. If the former
(unisymptomatic models) perform equivalent or superiorly to
syndromicmodels, a single syndromewould be a better description
of this patient population. If the latter (syndromicmodels) perform
better, the presence of 2 separate disorders would be supported.We
further used statistical clustering to find any natural syndromic
segregation within the patient cohort.
METHODS
Study design
Study data were collected prospectively at the Durham Bowel
Dysfunction Service, a single tertiary referral center in Northern
England. Approximately 50% of patients are referred directly
from their primary care physician (catchment area of 250,000
individuals) and the other 50% as tertiary referrals (catchment
area of 3million individuals). The study is reported in accordance
with the STROBE cohort study checklist (see Supplementary
Material, Supplementary Digital Content 9, http://links.lww.
com/AJG/B632). Ethical approval was obtained from the local
Research Ethics Committee (Ref: 09/H0906/86).
Study participants and data collection
Seven hundred sixty-eight consecutive adult patients with chronic
constipation attending the Durham Bowel Dysfunction Service
Table 1. Rome III and IV criteria for functional constipation
Rome III | Functional Constipation
For at least the last 3 months with symptom onset$ 6months ago;$ 2 of
the following (for. 25% of defecations):
Straining
Lumpy or hard stools
Sensation of incomplete evacuation
Sensation of anorectal obstruction/blockage
Manual maneuvers to facilitate defecation
,3 defecations per week
Must have both of the following:
Loose stools rarely present without laxative use
Does not meet Rome III criteria for IBS
Rome IV | Functional Constipation
For at least the last 3 months with symptom onset$ 6months ago;$ 2 of
the following (for. 25% of defecations):
Straining
Lumpy or hard stools
Sensation of incomplete evacuation
Sensation of anorectal obstruction/blockage
Manual maneuvers to facilitate defecation
,3 spontaneous bowel movements per week
Must have both of the following:
Loose stools rarely present without laxative use
Does not meet Rome IV criteria for IBS
Table 2. Rome III and IV criteria for irritable bowel syndrome
Rome III | Irritable Bowel Syndrome
Recurrent abdominal pain or discomfort, 3 days/month in the last 3
months, associated with $ 2 of the following:
Improvement with defecation
Onset associated with change in stool frequency
Onset associated with change in stool form (appearance)
Rome IV | Irritable Bowel Syndrome
Recurrent abdominal pain at least one day per week in the last 3 months
on average, associated with $ 2 of the following:
Related to defecation (increasing or improving pain)
Associated with change in stool frequency
Associated with change in stool form (appearance)
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over 7 years were invited to give their consent to have their data
recorded on a prospectivelymaintained database. All bar 2 patients
consented for study inclusion. This accrued a large and compre-
hensively phenotyped group of patients, albeit selective given that
all had symptoms severe enough towarrant tertiary center referral.
Data collection was prospective, protocol based and supple-
mented by careful validation from source data. Patients were
classified using the Rome III criteria (2), which were the gold
standard at the time of data collection, into those with IBS-C or
FC. Classification was assessed by proforma-based interview
questions undertaken by experienced clinicians, which included
the Rome III criteria for IBS-C and FC (2). All 6 coding clinicians
worked in the team for a minimum of 2 years and attended
regular team meetings. Patients with secondary causes of con-
stipation such as underlying neurological conditions or drug-
induced (including opioid-induced) constipation were excluded.
Other exclusion criteria included patients who did not fulfill the
diagnostic criteria for either IBS-C or FC, those with frequent
diarrhea (except when due to laxative use) suggestive of mixed
stool pattern IBS, or those who were unable to provide informed
consent. Patients with coexistent pelvic floor dysfunction (PFD)
were included (as per the Rome III classification), with symptoms
of PFD assessed by symptoms and defecating proctogram and
included in the statistical analysis. The rationale of this was that
although PFD can frequently coexist in this patient group, its
presence does not differentiate the disorders in current diagnostic
criteria. After exclusion criteria and removal of subjects with
missing data, this accrued a cohort of 661 patients, 365with IBS-C
and 296 with FC (see Supplementary Figure 1, Supplementary
Digital Content 5, http://links.lww.com/AJG/B621).
Demographic and clinical data were collected using a stan-
dardized proforma, adapted from the Cleveland Clinic Score (18),
with patients asked to provide information on duration of symp-
toms, age at onset of symptoms, symptom characteristics including
evacuatory dysfunction, abdominal pain, abdominal bloating, te-
nesmus, stool frequency, and stool consistency, as well as the re-
lationship of these symptoms to laxative use.These symptomswere
rated by the patient on a 5-point Likert scale (from 0 to 4). Stool
frequency and consistency were converted to the same categorical
scale according to predetermined groupings. All Rome III-based
symptom domains were also assessed by the clinician according to
standardized questions, allowing the classification of patients into
IBS-C or FC.As per the Rome criteria, where IBS-Cwas diagnosed,
FC was excluded (n 5 24) (2). Patients additionally reported the
presence of extracolonic symptoms, including genitourinary
symptoms (urinary frequency, nocturia, and stress incontinence),
and the presence of nausea and vomiting. All patients completed
the validated Patient Assessment of Constipation symptoms and
quality of life (QOL) questionnaires at their first clinic visit (19,20).
We chose not to use stool diary-based data measures. The reasons
for this were that first, the use of stool diaries in routine clinical
practice is not particularly high. Second,wewished to emulate data
variables that could be obtained from a general gastroenterology
clinic. Finally, we were aware of the argument that stool diaries can
confound data analysis by factors such as poor completion or
under-reporting of measures (21).
All patients underwent a radio-opaque marker transit study,
wherein transit time was determined according to a modified
Metcalf protocol (22). All laxatives were stopped for this assess-
ment. Both segmental and total transit were assessed, with capsules
of 24 identical markers administered on each of the first 3 days.
After the cessation of data collection, a period of data cleaning and
validity testing was performed, with retrospective searching of
medical records and investigation results to verify the accuracy of
data entry and to account for missing values. When this process
was completed, the database was locked for analysis to take place.
Statistical analysis
We provide a comprehensive description of all data measures
quantified and used in the analysis within the SupplementaryData
(see Supplementary Digital Content 4, http://links.lww.com/AJG/
B620). All statistical tests performed were corrected for multiple
comparisons by themeans of the Benjamini &Hochberg/Yekutieli
false-discovery rate to reduce the risk of type one error (23,24). All
P values depicted in the manuscript are corrected, and our false-
discovery rate-corrected statistical criterion was P, 0.05.
Principal component analysis
Given the large amount of data collected from each patient, it was
likely that there would be a number of redundant features. To
exclude any such redundancy, we used principal component (PC)
analysis to generate unique features, which would combine re-
dundant overlapping data. This approach is further described in
the Supplementary Material (see Supplementary Digital Content
3, http://links.lww.com/AJG/B619).
Supervised machine learning to differentiate IBS-C or FC
We usedmachine learning, an area of computer science whereby a
system can develop the ability to “learn”with data without explicit
programming. This advanced statistical modeling has gained sig-
nificant traction in recent years, both in the commercial sector,
such as with driverless cars or robotics, and academia/health care,
such as in automated lesion detection in endoscopy (25). A review
primer of machine learning with a focus to gastroenterology is
provided here for further reading (13). Specifically, we used ma-
chine learning to ascertain whether IBS-C or FC could be accu-
rately distinguishedbymodeling (13).Machine learning affords the
opportunity to build models, wherein a complex, multidimen-
sional set of features, such as patient demographic, symptoms,
examination findings, and investigation results, are coalesced to
predict an outcome—in this case, the patient’s diagnosis of IBS-C
or FC. Our rationale for this was that if a machine could accurately
distinguish and classify one diagnosis over another only when
using many features, it would support a distinction between the 2
disease groups as individual syndromes. However, should a model
be equally accurate when provided with a single feature only, i.e.
unisymptomatic, then it would support that the 2 disorders are not
distinct syndromes but rather are on a spectrum of that specific
feature. This approach is further discussed in the Supplementary
Material (see Supplementary Digital Content 3, http://links.lww.
com/AJG/B619).
Unsupervisedmachine learning to identify clustering patterns in
patients with chronic constipation
We considered that supervised machine learning models might not
support IBS-C and FC as distinct, multifaceted syndromes. Should
this be the case, we sought to determine if there was instead a robust
clustering structure of patients into disease phenotypes, i.e., a strictly
syndromicmodel using a large array of unique features. First, thiswas
used to ascertain if, when provided with clinical data, a machine
would identify the presence ofmultiple disease entities as per current
diagnostic criteria (i.e., IBS-C and FC). Second, we also considered



















that this unsupervised approachmay in fact yieldmultiple subgroups
withindisease phenotypes, or the converse, that in fact therewouldbe
no distinguishable groups at all. To investigate this, we undertook 2-
step cluster analysis, in addition todimension reductionwithuniform
manifold approximation and projection (UMAP),whichwe describe




After exclusion of 34 patients with secondary causes of con-
stipation, 25 who did not fulfill the Rome III diagnostic criteria for
either IBS-C or FC, and 48 patients with incomplete data, we in-
cluded 661 individuals (597 women, mean age 6 SD 41.76 6
15.38) in the final analysis (see Supplementary Figure 1, Supple-
mentary Digital Content 5, http://links.lww.com/AJG/B621). This
cohort consisted of 365 patients with IBS-C (322 [91.0%] women,
mean age 39.93 6 14.91) and 296 with FC (257 [86.8%] women,
mean age 44.02 6 15.68). Stool transit study results did not sig-
nificantly differ between the IBS-C and FC groups (see Supple-
mentary Material and Supplementary Figure 2, Supplementary
Digital Contents 3 and 6, http://links.lww.com/AJG/B619 and
http://links.lww.com/AJG/B622).
Principal component analysis identifies unique components of
chronic constipation
First, a pairwise correlation matrix of all clinical data was generated
(see Supplementary Figure 3, Supplementary Digital Content 7,
http://links.lww.com/AJG/B623). Kaiser-Meyer-Olkin measure of
sampling (0.72) and the Bartlett test of sphericity (P , 0.0001)
indicated that the data matrix was suitable for dimension reduction
techniques and therefore appropriate for machine learning later.
Oblimin with Kaiser normalization PC analysis (eigenvalue
threshold. 1) identified 23 PCs that accounted for 69% of the total
variance and converged in 44 iterations. The PCs with the largest
contributing variance and eigenvalues were as follows: (i) PC1: QOL
(which included self-confidence, condition obsession, dietary im-
pact, impact on daily routine, anxiety over dietary choices, stress,
decreased appetite, and embarrassment and upset regarding both
their condition and stool frequency), 20% of total variance, eigen-
value 17; (ii) PC2: viscerosensory (which included stomach dis-
comfort and cramping, frequency and severity of abdominal pain,
abdominal bloating, nausea and vomiting, Supplementary Data (see
Supplementary Digital Content 4, http://links.lww.com/AJG/B620),
5% of total variance, eigenvalue 4.3; (iii) PC3: stool frequency
symptoms, 5% of total variance, eigenvalue 3.6; and (iv) PC4: satis-
faction relating to disorder (including treatment), 4% of total vari-
ance, eigenvalue 3.1.A full list of PCswith respective eigenvalues. 1
and cumulative variance is shown in Figure 1, a–c. We also con-
sidered the possibility that these 23 retrieved features may not ade-
quately capture all important variance characteristics between IBS-C
and FC, given a variance coverage of 69%. Therefore, for subsequent
machine learning,we also expandedour syndromicmodel to include
all PCs to fulfill 95% of the total variance.
We reviewed the similarities, and dissimilarities, of the PCs
between IBS-C and FC. There were only 2 significant differences
between the diagnostic labels: (i) PC6: abdominal pain (which
specifically included abdominal pain related to stool frequency,
appearance of bowel movements, and association to defecation,
favoring patients with IBS-C to have more of these features (t
16.30; corrected P , 0.0001) and (ii) PC2: viscerosensory
favoring patients with IBS-C to report more viscerosensory
symptoms (t 4.33, corrected P , 0.0001). Individual parameter
constituents for these 2 PCs are available as Supplementary Data,
(see Supplementary Digital Content 4, http://links.lww.com/
AJG/B620). Notably, PC6 was not the sole component featuring
visceral pain either—PC23: rectal pain/bleeding showed no sig-
nificant difference between the diagnostic groups (t 2.40, cor-
rected P . 0.05). The remaining PCs were not significantly
different, which included symptom domains, QOL measures,
demographics, stool frequency measures, and transit time. Strip
plots of individual patients, per diagnosis, per PC (with eigen-
value . 1), are shown in Figure 1d, which also highlights the
considerable overlap between the 2 groups in nearly all domains.
Abdominal pain alone is necessary and sufficient for
differentiating IBS-C and FC
Having dimension reduce the data into distinct features (PCs),
we used machine learning to compare the accuracy of diagnos-
tic models based on single differentiating characteristics (uni-
symptomatic) vs multiple characteristics (syndromic). The
specific predictive aim was to classify patients into their Rome III-
derived diagnostic label of either IBS-C or FC.
First, we trained a unisymptomatic classifier to predict a di-
agnosis of IBS-C or FC using PC6: abdominal pain alone. All
models performed near perfectly at distinguishing IBS-C and FC
(all area under the curves [AUCs] 0.97) (Figure 2a). Second, we
trained a classifier using PC2: viscerosensory alone. These models
performed poorly, the “best” performer of which was the neural
network (AUC 0.64) (Figure 2b). Next, we trained a syndromic
classifier using all PCs, which totaled 95% of the cumulative vari-
ance of the total dataset. This included the 23 PCs with eigenvalues
. 1 (as depicted in Figure 1), but additionally a further 31 PCs (all
of which had eigenvalues ranging from 0.44 to 0.99). Best model
performance was the neural network (AUC 0.98) (Figure 2c). Di-
agnostic accuracy of the best performing syndromicmodel did not
differ significantly from the best performing unisymptomatic
model using PC6: abdominal pain alone (P . 0.15). Of note, the
abdominal pain unisymptomatic K-nearest neighbor model per-
formed significantly better than the fully syndromic model (P ,
0.0008), suggesting that, in fact, the presence of features other than
abdominal pain was confusing to themodel in differentiating the 2
disorders, rather than being beneficial.
We then evaluated the performance of the syndromic model
using all PCs (totaling 95% of cumulative variance), except we
withheld the PC6: abdominal pain feature. These models all
performed poorly with chance-level accuracy, the best model of
which was a Gaussian naive Bayes (AUC 0.63). This syndromic
model performed significantly worse than the unisymptomatic
PC6: abdominal pain model (P , 0.0001) (Figure 2d). We
reviewed the individual patients misclassified by the full-feature
syndromic model (Figure 2, e and f). Patients who were wrongly
classified by the model seemed to rely strongly on PC6, the ab-
dominal pain component. Individuals who were wrongly classi-
fied by the model as FC (Figure 1e; blue dots), but actually had a
clinician-provided diagnosis of IBS-C, seemed to have degrees of
pain which overlapped that of the accurately classified patients
with FC (Figure 1e; orange dots). Similarly, those who were
wrongly classified by the model as having IBS-C (Figure 1e; pink
dots), but actually had a clinician-provided diagnosis of FC,
seemed to have degrees of pain which overlapped the accurately
classified patients with IBS-C (Figure 1e; green dots). This pattern
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was not apparent for any of the remaining PCs, wherein there was
considerable overlap.
Pain is only discriminative for IBS-C over FC if it directly features
in diagnostic criteria
Having ascertained PC6: abdominal pain as the key feature in
whether a model would diagnose IBS-C accurately or in-
accurately (Figure 2), we investigated this specific component
and its individual constituents in greater detail. We identified
that by only using the pain measures in PC6 that do not directly
factor into the diagnostic criteria for IBS, the model then
becomes unable to separate the patient groups accurately; the
accuracy of the best performing model was 53% (see Supple-
mentary Material, Supplementary Digital Content 3, http://
links.lww.com/AJG/B619 and Supplementary Figure 4, Sup-
plementary Digital Content 8, http://links.lww.com/AJG/
B624). Therefore, in our sample, the only factors which allow
IBS-C and FC to be distinguished by machine learning were
abdominal pain measures that form part of the diagnostic
criteria.
Figure 1. All disease components of chronic constipation are equivalent between IBS-C and FC, except for abdominal pain and viscerosensory measures.
(a) PCA identified 23meaningful components listed in descending order of eigenvalue (b), which cumulatively accounted for 69% of the total variance (c).
(d) PCs were compared between IBS-C and FC groups, which revealed the groups to be largely similar, with the exception of PC2: viscerosensory and PC6:
abdominal pain (bothdemarcatedwith dotted lines). (e) Per-component results of thebest-performingmachine learningclassifier in diagnosing IBS-Cor FC
(Figure 2). Patients who are wrongly diagnosed by themodel seem to hinge exclusively on PC6: abdominal pain, wherein if a patient waswrongly diagnosed
as IBS-C (i.e., actually having FC, pink dots), their PC6 pain value was closer to the IBS-C group (green dots) and vice versa. FC, functional constipation;
Freq., frequency; GU, genitourinary; IBS-C, irritable bowel syndrome with constipation; Lax, laxative; PC, principal component; PCA, principal component
analysis; PR, per rectum; Slf-Cont, self-control; sym, symptoms.



















Unsupervised machine learning clusters patients into
syndromes by disease impact
We sought to determine if syndromic segregation of chronic
constipation patients was apparent using unsupervised learning
to do so in a data-driven way. Two-step cluster analysis iden-
tified the best silhouette fit of possible outcomes was the par-
cellation of patients into 2 disease clusters. Cluster 1 contained
421 (63.7%) patients, with the remaining 240 patients allocated
to cluster 2 (36.3%). The feature weights which determined al-
location to cluster 1 or 2 were reviewed. These identified that
disease impact and QOL domains held the highest importance,
including adverse effect on dietary habit, worry, and anxiety
over stool frequency, viscerosensory measures, embarrassment,
and QOL itself (Figure 3, a and b). A diagnostic label of IBS-C or
FC was weakly predictive only, which had equivalent predictive
power to PC6: abdominal pain, an expected outcome given that
the 2 disorders are seemingly differentiated by this measure
alone. By using the Fisher exact test, a diagnosis of IBS-C over
FC was weakly significant in allocation to cluster (corrected P,
0.03). We additionally compared cluster allocation, aligned to
diagnostic label and individual PC features, which showed
considerable overlap between the diagnoses in all domains ex-
cept for abdominal pain, where the 2 separated, as would be
expected (Figure 3c). We cross-compared the findings of our 2-
step cluster analysis, which used all 23 PCs, to an independent
analysis of all raw data using UMAP (26). This confirmed these
findings, namely that 2 clusters exist that hinge on the impact of
disease on daily life, which held negligible relationship to di-
agnostic label (Figure 3, d–e).
We examined the cluster profiles for patients using afore-
mentioned feature (node) importance and feature correlations
(edges). Stochastic block modeling was used to identify com-
munities of similar patients. This was exponentially weighted by
feature importance and feature-feature correlation, which gen-
erated undirected weighted networks of how constipation fea-
tures interact as a network (Figure 4). These enabled us to review
the complex network-like interaction between many features in a
syndromic fashion. For instance, the cluster 1 node of dietary
disturbance strongly connected to greater worry and embar-
rassment that strongly related to worse overall QOL, which in
itself was also related directly to dietary disturbance. For example,
in cluster 2, less dietary disturbance was strongly linked to less
Figure2.Abdominalpainalone isnecessaryandsufficient fordifferentiating IBS-CandFC. (a)Unisymptomaticmodelsof abdominal pain (PC6)achievednear-
perfect accuracy indistinguishing IBS-C andFC. (b)Models of viscerosensorymeasures (PC2) performpoorly. (c) There is no significant improvement inmodel
accuracy when a syndromic feature set is used in place of a unisymptomatic pain feature. (d) Syndromic feature set models, when excluding PC6: abdominal
pain, shows chance-level accuracy. (e) Two-dimensional plot of the 2 components which significantly differed between patients with IBS-C and FC, PC2:
viscerosensory andPC6: abdominal pain, with patients with IBS-C having bothworse pain and other viscerosensorymeasures. The2 diagnoses arguably seem
distinct with these data alone, illustrated with dotted line approximately separating the groups. (f) Two-dimensional plot of the 2 components, with the results of
the best-performing classifier plotted. Namely, patients wrongly classified as either diagnosis seem to fall on the “wrong side” of the diagnostic line, not
conforming to the stereotype of the diagnosis of FC or IBS-C (i.e., patients with FC having abdominal pain features expected in IBS-C, and patients with IBS-C
having abdominal pain features expected in FC). FC, functional constipation; IBS-C, irritable bowel syndrome with constipation; PC, principal component.
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bloating that was linked to less viscerosensory symptoms, which
was strongly linked to less abdominal pain.
To formally test the validity of these newfound clusters as
syndromic segregations, we trained classification models with
sequential feature addition and statistically compared the
performance (Figure 5). First, a unisympatomatic (single fea-
ture) model using PC10: diet (statistically the most predictive
feature, see Figure 3) achieved a best possible accuracy with a
logistic regression (AUC 0.74) (Figure 5a). We next retrained
the classifier using the 5 most predictive features (Figure 3a),
the best model being a linear support vector machine (SVM)
(AUC 0.87), performing significantly better than the single
feature model (P, 0.0001) (Figure 5b). This performance was
further improved when using the 10 most predictive features,
the best model being a coarse Gaussian SVM (AUC 0.94),
significantly more accurate than the 5-feature model (P ,
0.0003) (Figure 5c). We finally evaluated model performance
using all PCs which, after multiple comparison, significantly
differed between cluster 1 and 2 (Figure 3a), an 18 feature
model. This fully syndromic model performed well, the best
model being a quadratic SVM (AUC 0.99), significantly more
accurate than the previous 10-feature model (P , 0.0001)
(Figure 5d).
DISCUSSION
A valid clinical classification is either based on a known patho-
genesis or clear differences in diagnostic (clinical or investigatory)
criteria. A definition of a syndrome as a unique disease entity is
one that differs from another disorder according to multiple
features. A valuable classification is one that defines treatment
Figure 3.Unsupervised learning clusters patients with chronic constipation patients into syndromes by disease impact. (a) Feature importance, by PC, in
allocation to cluster 1 or cluster 2, where values tending to 1 are of higher importance. (b) Box and whisker plots illustrating the differences between
clustered groups. (c) Box and whisker plots illustrating the differences between diagnostic labels and cluster groups show that diagnoses only differ with
abdominal pain. (d) UMAP embeddings of all raw features illustrate no convincing visual distinction between IBS-C and FC. (e) Rather, UMAP embeddings
align well to our independent cluster derivation. FC, functional constipation; Freq., frequency; GU, genitourinary; IBS-C, irritable bowel syndrome with
constipation; Lax, laxative; PC, principal component; PCA, principal component analysis; PR, per rectum; Slf-Cont, self-control; sym, symptoms; UMAP,
uniform manifold approximation and projection.



















responses. The classification of constipation into FC and IBS-C is
necessarily an arbitrary one because the pathogenesis of these
conditions remains unclear. One of the difficulties with this
classification is the need for an exclusion clause because many
patients fulfil both FC and IBS-C criteria, in which case the IBS-C
diagnosis takes priority. This explains much of the overlap, but
the question still remains as towhether the classification identifies
any other meaningful differences.
The initial dichotomous use of the classification has been
tempered in recent years with the Rome IV criteria, suggesting
that they represent a spectrum (27), one seemingly focused on
abdominal pain, which our data support. The classification has
also been shown to be temporally unstable, with approximately
one-third of patients across either disease label switching to the
other label 12 months later (8). However, other researchers
claim important differences between the subtypes (28,29), and a
recent study proposed subtype differences that hinge on vis-
cerosensory, extraintestinal, somatic, and psychological vari-
ables (28), a hypothesis that our clustering findings also support.
We demonstrate that chronic constipation, as a disease entity,
comprises a number of features. These components are multifaceted
and vary in nature, from QOL domains, stool frequency measures,
Figure 4. Network-based cluster profiling in chronic constipation hinges on disease impact. Disease networks of cluster 1 (a) and 2 (b). Node size and color
indicate importance of a particular node in the profile, with edge color andwidth corresponding to correlation strength between nodes (key). Abdo., abdominal;
Dis, disease; Diff., difficulty; Disturb., disturbance; Freq, frequency; Impair., impairment; Embar., embarrassment; F, female; GU, genitourinary; Lax., laxative;
o/, over; PR, per rectal; QOL, quality of life; Rc., rectocele; Sens., sensory; SC., self-confidence; sym, symptoms; Ts, transit study speed; Tx, treatment; w/, with.
Figure 5.Clustering of patients by disease impact is a valid syndromic classification. ROCplots ofmodel performance in distinguishing patients fromcluster
1 vs cluster 2. (a) Single feature (unisymptomatic) model ROCs. (b) 5-feature model ROCs. (c) 10-feature model ROCs. (d) 18 feature (fully syndromic)
model ROCs, which have best predictive accuracy. ROC, receiver operator characteristic.
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symptommeasures, viscerosensory (includingpain)measures, clinical
examination, and investigatory findings. Using a machine learning
approach to investigate whether FC and IBS-C represent distinct
subgroups, we show that of the dimensions that seem to make up
chronic constipation, only abdominal pain and viscerosensory mea-
sures differ significantly between these putatively distinct disorders.
Moreover, using machine learning, a model is able to differentiate
accurately between the 2 disorders only when abdominal pain data
that directly factors into current accepted diagnostic criteria are sup-
plied; without these data, the model performs at a level of chance.
Other measures of pain that do not feature in the diagnostic classifi-
cation for IBS show no meaningful predictive value during machine
learning either. We show that patients with symptoms of chronic
constipation exhibit syndromic clustering, but this is defined most
importantly by the impact of the disease on their life, not by the
diagnostic label these patients are given. It would be prudent to eval-
uate these findings in other geographical regions and nonspecialist
centers to ensure generalizability. Of limitation in this study, there are
somequantitativephysiologicalmeasureswedidnot ascertain, suchas
gutmicrobiotaorcolonicMRI,although itwas felt that the inclusionof
methods not routinely used in current clinical practice were not as
justifiable and would limit generalizability outside of a tertiary center.
Future studies should establish the additive value insofar as predicting
one diagnosis over the other or whether this would influence our
newfound clustering pattern.
Clinically, the treatment of the 2 subgroups is often highly
similar, with drugs that have laxative effects. This is with the
caveat that by virtue of these diagnostic criteria, an evidence
base for different treatment options exists because a literature
of randomized controlled trials for “people with IBS,”
i.e., those with more abdominal pain, and to a lesser extent,
“people with FC,” i.e., those with less abdominal pain, has
been developed. We argue that the presumption the 2 are
distinct disorders can lead to a situation where it is unclear
whether some treatments are helpful or not see Table 2 of ref.
7. An example of this in the United Kingdom is the National
Institute for Health and Care Excellence licensing of linaclo-
tide for IBS-C (30), whereas lubiprostone is licensed for
chronic idiopathic constipation (31), despite the literature
illustrating efficacy of linaclotide for both conditions (32).
This is especially the case for treatments where effectiveness
has been ascertained principally by stool frequency measures,
such as spontaneous bowel movements, as opposed to a spe-
cific focus on pain. Given that we fail to show differences in
these stool frequency or transit measures between patients
with FC and IBS-C, we therefore question the appropriateness
of their segregation. Of course, treatments specific to atten-
uating visceral pain may differ, but it could be construed the
reason for this is because the 2 disorders are segregated by the
presence of visceral pain anyway, arguably a self-fulfilling
difference.
Although we show that the diagnoses of IBS-C and FC are
essentially inseparable in our data set, other than for the
presence of pain, we identify a clustering pattern of patients
whose chronic constipation, in general, has a greater impact on
their everyday life. These patients, belonging to cluster 1
exhibited markedly greater dietary disturbance, greater worry
and embarrassment regarding their stool frequency, and
greater viscerosensory disturbance, as well as numerous other
measures, with the converse profiling being true for patients in
cluster 2. Furthermore, these domains, although individual in
their own right (such as rectal pain), all inter-relate to provide a
highly complex and organized disease network, such as rectal
pain connecting to tenesmus, which in turn connects to a lower
treatment satisfaction and so on. We validate that this network
of features is in keeping with syndromic segregation, wherein
predictive accuracy of models improves significantly with the
incremental addition of features (therefore favoring the syn-
dromic definition of disease as opposed to solely uni-
symptomatic difference). Future studies should seek
pathophysiological differences and investigate best therapeu-
tic algorithms related to these clusters.
In summary, we report that in a large number of patients
with chronic constipation labeled with either IBS-C or FC, the
2 groups show negligible differences across all demographic
data, symptomatology, examination, and transit studies. We
show that, using machine learning, algorithms can accurately
diagnose IBS-C over FC only when abdominal pain measures
directly factored into the Rome III criteria are available.
Machine learning supports the 2 disorders to be uni-
symptomatically different, i.e. disorders lying on a one-
dimensional spectrum, rather than disparate syndromes.
Treatments currently considered for either IBS-C or FC may
be equally effective for the alternate diagnostic label, espe-
cially where the primary aim is to increase spontaneous bowel
movements, which needs future evaluation in clinical trials.
Furthermore, we illustrate with machine learning and
graphical networks that patients with chronic constipation do
separate into 2 clusters, but these clusters are a syndromic
network of inter-relating disease factors that impact on a
patient’s life, as opposed to diagnostic label. Further research
is required to evaluate the value of this diagnostic classifica-
tion system, whether pathophysiological differences are ap-
parent and whether effective treatments differ between these
newly identified syndromic clusters. In particular, treatments
that moderate abnormal sensation should be sought, not just
those that increase transit and stool production. The outcome
measures for clinical trials may need modification. Person-
alization of treatment regimens for chronic constipation
based on these novel, network-based, syndromic clusters may
be beneficial.
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Study Highlights
WHAT IS KNOWN
3 Chronic constipation is presently classified into 2 main
syndromes—IBS-C and FC.
3 The segregation of these as separate syndromes assumes
that they differ along multiple clinical characteristics and are
plausibly of distinct pathophysiology.
3 Previous studies have questioned the mutual exclusivity of
IBS-C and FC as disease entities, suggesting instead that the
2 lie on a single spectrum.
WHAT IS NEW HERE
3 Using machine learning, IBS-C and FC differ only by a single
feature, abdominal pain, a self-fulfillling difference given that
abdominal pain inherently distinguishes the 2 in current
diagnostic criteria. These disorders therefore do not differ
syndromically, but unisymptomatically.
3 In chronic constipation, 2 clusters of patientsdo exist but bear
negligible resemblance to the diagnostic labels of IBS-C and
FC. Rather, these clusters of patients are separated by a
complex network of features, including diet disturbance,
viscerosensory disturbance and QOL.
3 This has significant implications for both diagnostic
classification systems and treatment algorithms. We propose
an alternative, data-driven and validated as syndromic,
segregation of patients with chronic constipation.
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